Congenital melanocytic naevi. Who benefits from a therapy?

Krengel, Sven

doi:10.1111/bjd.18706

Br J Dermatol

2020

DOI: 10.1111/bjd.18706

|View full text |Cite

Congenital melanocytic naevi. Who benefits from a therapy?

Sven Krengel¹

Abstract: Linked Article: Polubothu and Kinsler. Br J Dermatol 2020; 182:721–728.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Aanpak en behandelingsopties voor congenitale melanocytaire naevi

Vanneste¹,

Garmyn²,

Morren³

2021

Tijdschr Geneesk

View full text Add to dashboard Cite

Management and treatment options in congenital melanocytic nevi Congenital melanocytic nevi (CMN) are benign collections of nevus cells in the skin. They are present at birth or arise during the first weeks of life. Depending on the size, they appear in 1 in 100 to 500.000 live births. CMN are associated with a variety of benign conditions such as benign proliferations, certain facial characteristics or subtle endocrine dysfunctions as well as malign developments such as melanoma and neurological complications. The risk for these complications strongly depends on the clinical phenotype. Magnetic resonance imaging (MRI) has a strong value in estimating the risk of these complications. A normal MRI of the central nervous system results in a lower risk of developing melanoma and neurological complications because of the thorough follow-up and early capture. Although there are various treatment modalities, a shift to more conservative treatment is seen. Little is known about the long term prognosis after treatment of CMN. This article tries to give a recommendation for treatment and follow-up of CMN based on the current literature.

show abstract

Aanpak en behandelingsopties voor congenitale melanocytaire naevi

Vanneste¹,

Garmyn²,

Morren³

2021

Tijdschr Geneesk

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Congenital melanocytic naevi. Who benefits from a therapy?

Abstract: Linked Article: Polubothu and Kinsler. Br J Dermatol 2020; 182:721–728.

Cited by 1 publication

References 6 publications

Aanpak en behandelingsopties voor congenitale melanocytaire naevi

Aanpak en behandelingsopties voor congenitale melanocytaire naevi

Contact Info

Product

Resources

About